Innovations • Global Impact • In The News • Our People
RSV Vaccine Made Possible With Adjuvant Technology
The FDA approved Arexvy, GSK's RSV vaccine, to prevent hospitalizations in adults 60+ years old. The vaccine incorporates GSK's AS01 adjuvant formulation. Learn more about the importance of adjuvants and how they play a role in protecting vulnerable populations against various diseases.
The latest scientific breakthroughs at AAHI.
AAHI's adjuvanted TB vaccine candidate is safe and induces a strong immune response in BCG-vaccinated participants in a Phase 2 clinical trial.
Clinical trial results demonstrate that AAHI's TB vaccine candidate, ID93 + GLA-SE, maintains a good safety profile and induces strong immune responses, including Type 1 T-helper cellular immune responses that are typically difficult to induce but are critical to fighting TB. The results of Phase 2 clinical trials sponsored by Quratis in South Korea (NCT03806686) were published in Infectious Diseases and Therapy.
Make your products accessible to those who need them most. Collaborate with AAHI.
Collaboration across communities.
Explore AAHI's different areas of impact.
World Malaria Day 2023 - Time to deliver zero malaria: invest, innovate, implement
AAHI provides adjuvant formulations to partners around the world to enable cost-effective malaria vaccine candidates that can be made equitably accessible to people in areas most burdened by malaria-carrying mosquitoes, such as Africa, India, and Brazil. Although malaria is curable, malaria parasites claimed over 600,000 lives and infected 200 million people in 2021 alone. While travelers like Seattle Sounders' Nouhou Tolo can return home to access treatment, the treatment is not ready accessible to residents of, for example, Uganda, Mozambique, and Tanzania. The sole approved malaria vaccine, Mosquirix, is approved in Ghana and Nigeria for young children, but there continues to be an urgen unmet global need for malaria vaccines for older children, adults, and pregnant women.
Learn more about malaria vaccine candidates targeting varous strains of the disease that are in clinical development.
Help us make impossible vaccines possible.
NEWS WE FOLLOW
By Anthony King
One of the most successful vaccine adjuvants – QS-21 – is derived from saponin compounds in the bark of the rare Chilean soapbark tree Quillaja Saponaria. QS-21 is a component of GSK’s Shingrix®, Mosquirix®, and Arexyv® vaccines, Novavax’s Nuvaxovid® vaccine, and several leading malaria and tuberculosis vaccine candidates. Researchers are exploring more sustainable ways to source saponin to keep up with growing demand.
Scientists at John Innes Centre in Norwhich, UK, identified the specific pathway by which Chilean soapbark trees synthesize saponins. This isa significant step toward understanding how these rare trees can be induced to produce saponin in parts of the tree other than its bark, for more sustainable and higher volume production.
Collaboration across communities.
Explore our different areas of impact.
Openings and Opportunities
The Scientist I/II (Product Development) will be responsible for establishing, managing, and executing process development, formulation development, and delivery device development and testing and associated analytical capabilities.
The Scientist I/II/Senior Scientist will be responsible for broadening the applications of AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets and will lead a growing, multi-level, early development team to bring novel RNA vaccine candidates to the initiation of Phase 1 clinical trials.
Learn more about our formulation technology
We partner with biotech leaders to develop vaccines and more.
See how our formulations are being used.
Sign up to stay in touch!
Get the latest news and updates in your inbox every month and learn more about how our scientists are developing equitably accessible vaccines and therapeutics for people who most need them.